Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01015 vs Opdivo in advanced esophageal squamous cell carcinoma
NCT06022861Phase 3Active, not recruiting
- Sponsor
- Boan Biotech
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LY01015 in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Boan Biotech. Primary endpoint: Objective Response Rate at 16 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
LY01015
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06022861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022861.